A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
about
Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signalingDynamic antagonism between RNA-binding protein CUGBP2 and cyclooxygenase-2-mediated prostaglandin E2 in radiation damageInherited colorectal cancer syndromesMolecular cancer prevention: Current status and future directionsDuodenal adenoma surveillance in patients with familial adenomatous polyposisChemoprevention in familial adenomatous polyposisEffect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and realityPotential use of COX-2-aromatase inhibitor combinations in breast cancerNonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapyCan resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 StudyRole of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experienceDrug development against metastasis-related genes and their pathways: A rationale for cancer therapyInhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humansCyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins.Mouse models of human familial cancer syndromes.A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract.In the beginning there was colectomy: current surgical options in familial adenomatous polyposis.P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosisSelective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP.Mouse models of inherited cancer syndromesDuodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controlsThe oncomodulatory role of human cytomegalovirus in colorectal cancer: implications for clinical trials.The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management.Pancreaticoduodenectomy for advanced duodenal and ampullary adenomatosis in familial adenomatous polyposisTegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair.Dual roles of immune cells and their factors in cancer development and progressionRecent randomised trials in colorectal disease.Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.Non-steroidal anti-inflammatory drugs and colorectal cancer preventionCan we safely target the WNT pathway?Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma.Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective studyDuodenal adenomatosis in familial adenomatous polyposis.Prevention and management of duodenal polyps in familial adenomatous polyposis.COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?Endoscopic management of nonampullary duodenal polyps.Chemoprevention in gastrointestinal physiology and disease. Targeting the progression of cancer with natural products: a focus on gastrointestinal cancer.Molecular markers that predict response to colon cancer therapy.
P2860
Q21245755-E8E11D3C-B0CE-4B61-A1CF-5EE1C48FA0E9Q24564600-EA25B468-3429-49D7-B461-41DD50E9DA89Q24628009-72A95C11-8023-4CC1-93AD-85DB8F43401FQ26797207-F0F77EC1-F5AC-4AC8-9081-6AA62E0D9FEEQ26799039-F4C77C6A-5035-4BF2-B03C-6FDBF119A39CQ27023845-ECAB1DFE-1950-41BB-8FA4-6C2595440F15Q27347642-3A13CA96-CD9C-4FAB-BDA5-28700937DF91Q28166312-2265595D-9245-4F26-9D02-D17F9B38F5DDQ28187414-5B1645B0-A630-486C-B3EE-EA6144F0F1CDQ28195436-3A793415-4931-4710-9D96-6273C4CFAA9EQ28195925-CAFAED8E-7212-4919-A644-78C07A040E2CQ28303196-90FB7A6B-04C0-4E17-AC7F-7ADBCAB855FBQ29010479-0BB2A012-C3F9-4A35-832F-E40AD3841676Q30486725-041CEEE7-2E44-4B69-9B6D-EFEB60F884F6Q30494961-56B99037-A3C1-47E0-8BCD-BB8FE5BF55D8Q33204054-EDD5C280-8915-423E-9C35-AEA70F21F174Q33640357-D2C47A77-83A8-4340-AF1D-1F34A1488BF4Q33664095-9F7EAFA6-7F77-4930-8506-C2677B25D1FEQ33732318-51AE7CEA-F2A3-4BA5-BCE3-5B1C96D186A3Q34207195-B67C6889-7F2F-4F11-AB15-FA1723D0F313Q34306499-D1E2D783-2714-4238-B4BD-A2D52D11B04AQ34447472-D147026F-5113-42A8-9736-B53B38D1CB25Q34478110-A8ECF4D8-35C2-4DBA-A8BF-FFC4C8A987CAQ34521746-0676B2C6-0E35-46E4-BC4D-BE9EF4B105B6Q34669614-B725D9B1-4726-4835-BBBD-0BB1FCECEC8DQ34978331-831CC376-7E8B-4B5D-BDE6-1BA8A3EDB281Q34997967-FDEA022A-44CD-49E3-A510-FBD82899B196Q35022538-2E5963F2-D73B-4DEF-8C00-31FA764EC1E7Q35157518-1B74330F-8741-49F7-8178-D97A19BB8116Q35374477-8FD91412-7B9F-4391-AB80-F8EBF5C98B67Q35521719-A93FCB64-14BF-4846-BB5A-2EC3FE36F04CQ35591995-623B7E16-A85F-4A1F-B1E7-0716583747ECQ35593681-6BA8ED76-F2BD-4C4B-A0FD-D8C4645A82ACQ35594612-2DE6553E-E4F1-44DA-AA14-21D7D27C00CCQ35596339-5EE70132-B752-4198-8035-D13BC9200B2DQ35597651-57A958E9-BC9D-43B7-AE12-6CD99ADD922BQ35753467-2605ECF4-B997-4D6F-86B8-4A738D358BCDQ35810195-E6E7F203-CD34-4234-BC63-13310F6AA412Q35928052-B8A4A700-363E-453C-8BB0-A57566465CDCQ36150356-B6ED6F38-AC54-4077-9CB5-098B823925C9
P2860
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@ast
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@en
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@nl
type
label
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@ast
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@en
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@nl
prefLabel
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@ast
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@en
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@nl
P2093
P2860
P356
P1433
P1476
A randomised, double blind, pl ...... amilial adenomatous polyposis.
@en
P2093
B P Saunders
FAP Study Group
G B Gordon
G Steinbach
P2860
P304
P356
10.1136/GUT.50.6.857
P407
P577
2002-06-01T00:00:00Z